Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin.

  • Zohreh Heidari Digestive Oncology Research Center Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Kiana Shahzamani Department of Biology, Faculty of Sciences, Lorestan University, Khorram-abad, Iran.
  • Reza Ghanbari Digestive Oncology Research Center Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Arash Tahamsebifar Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Keywords: Hepatitis C Virus (HCV), Single nucleotide polymorphism (SNP), α-Interferon receptor


Hepatitis C Virus is one of the main reasons for chronic liver disease and hepatocellular carcinoma. Combination therapy with Interferon (peg-IFN-α) and Ribavirin (RBV) clear the virus more likely than the others. Different factors like virus and host characteristics influence on response to treatment. The most important viral factors include virus genotype and viral load; host factors like genetic, gender, race, age, weight and liver enzymes are also important. Previous studies have shown that single nucleotide polymorphisms (SNPs) in IFNR genes can regulate and influence on treatment with IFN. The purpose of this study is to investigate the association between SNPs in IFN-α receptor (IFNAR1 & IFNAR2) genes among subjects affected with chronic hepatitis C, who have treated with IFN and RBV, and also relationship between HCV genotypes and response to combination antiviral therapy. Peripheral blood mononuclear cells (PBMCs) were taken from whole blood of 61 patients affected with chronic hepatitis C who were treated with IFN and Ribavirin. Then, DNA was extracted from PBMCs and quality of DNA was assessed with Nanodrop finally two SNPs [Ex4-30G>C] and [Ivs1-4640 G>A] of IFN receptor genes (IFNAR1 and IFNAR2) were measured by TaqMan Real-Time PCR in ABi Prism 7900 system. Also to confirm the response rate to therapy, RNA was extracted then RT PCR was performed and final product was studied with gel electrophoresis and UV spectroscopy. Statistical analysis was performed using SPSS version 18.0 for Windows. The analysis of results from TaqMan SNP Genotyping has been shown that two SNPs (Ex4-30G>C and Ivs1-4640 G>A) of IFNAR1 and IFNAR2 didn't show any relationship with response to combined therapy in subjects affected with chronic hepatitis C who have treated with peg-IFN-α and Ribavirin. 61 patients complete the treatment period. 54 patients (%88/5) of them responded to treatment and 7 patients (%11/5) did not. Research and data analysis have shown that there is no significant relationship between sex (P=0 /7) and age (P=0 /2). But there is a relationship between genotype-3a and response to combined therapy of IFN-α and RBV (0/02). Studies have shown that gene polymorphisms in IVSS1-22G location of IFNAR1 gene had a relationship with IFN treatment response. But current study has shown that there is no significant relationship between two SNPs Ex4-30G>C and Ivs1-4640 G>A and response to IFN therapy. In continue we suggest that it would be better to use this technique to evaluate other SNPs in IFN genes.


Manns MP, Cornberg M, Wedemeyer H. Current and future treatment of hepatitis C. Indian J Gastroenterol 2001;20(Suppl 1):C47-51.

Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355(9207):887-91.

Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341(8):556-62.

De Bac C, Strofffolini T, Gaeta GB, et al. Pathologic factors in cirrhosis with and without hepatocellular carcinoma: A multicenter Italian study. Hepathology 1994;20(5):1225-30.

Randall RJ. Hepatitis C virus infection and long-term survivors of childhood cancer: issues for the pediatric oncology nurse. J pediatr Oncol Nurs 2001:18(1):4-15.

Bonkovsky HL, Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol 2001;44(2):159-82.

Alter MJ. Epidemiology of hepatitis C. Hepatology 1997:26(3 Suppl 1):62S-65S.

Sterling RK, Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep 2006;8(1):53-9.

Xia X, Luo J, Bai J, et al. Epidemiology of HCV infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008;122(10):990-1003.

Imperial JC. Chronic hepatitis C in the state prison system:= insights into the problems and possible solutions. Expert Rev Gastroenterol Hepatol 2010;4(3):355-64.

Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010;52(4):1497-505.

Pondé RA, Mikhaĭlova A. Hidden hazards of HCV transmission. Med Microbiol Immunol 2011;200(1):7-11.

Jafari S, Copes R, Baharlou S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and metaanalysis. Int J Infect Dis 2010;14(11):e928-40.

Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000;7(4):250-7.

Mabee CL, Crippin JS, Lee WM. Review article: interferon and hepatitis C-factors predicting therapeutic outcome. Aliment Pharmacol Ther 1998;12(6):509-18.

Camma C, Giunta M, Pinzello G, et al. Chronic hepatitis C and interferon alpha: Conventional and cumulative Metaanalyses of randomized controlled trials. Am J Gastroenterol 1999;94(3):581-95.

Camma C, Giunta M, Linea C, et al. The effect of interferon on the liver in chronic hepattis C: A quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26(6):1187-99.

1 Benvegnu L, Pontisso P, Cavalletto D, et al. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997;25(1):211-5.

Lai MY. Firstline tretment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy. J Gastroenterol Hepatol 2000;15(Suppl):E130-3.

Rezvan H, Ahmadi J, Farhadi M, et al. A preliminary study on the prevalence of anti-HCV among healthy blood donors in Iran. Vox Sang 1994;67(Suppl):100.

Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436(7053):967-72.

Liu WL, Su WC, Cheng CW, et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis 2007;196(3):425-34.

Pawlotsky JM. How does ribavirin improve interferon- [alpha] response rates in hepatitis C virus infection? J Hepatol 2005;42(6):951-3.

Manzin A, Bagnarelli P, Merzo S, et al. Quantitation of Hepatitis C Virus Genome Molecules in plasples. J Clin Microbiol 1994;32(8):1939-44

Tena-Tomas C, pedroso ML, de Messias-Reason IJ, et al. Polymorphisms in the IFNAR1 gene in patients with chronic hepatitis C: outcome of combined IFN-α therapy. Eur Cytokine Netw 2007;18(3):136-41.

Nakano T, Lau GM, Lau GM, et al. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 2012;32(2):339-45.

Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011;364(25):2429-38.

Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007;(4):CD003620.

Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of Hepatitis C. Ann Intern Med 2000;132(4);296-305.

Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005;436(7053):933-8.

Romero AI, Lagging M, Westin J, et al. Interferon (IFN)- gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006;194(7):895-903.

Kawamura Y, Arase Y, Ikeda K, et al. The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load. Intern Med 2008;47(5):355-60.

Morgan TR, The HALT-C Trial Group. DNA Polymorphisms and response to treatment in patients with chronic hepatitis C. J Hepatol 2008;49(4):548-56.

Wilkins T, Malcolm JK, Raina D, et al. Hepatitis C: diagnosis and treatment. Am Fam Physician 2010;81(11):1351-7. 35. Awad T, Thorlund K, Hauser G, et al. Peginterferon alpha- 2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51(4):1176-84.

Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response diffirence in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003;37(6):1343-50.

Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial difference in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999;30(3):787-93.

Nelson DR, Tu Z, Soldevila- Pico C, et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-Inflammatory effect. Hepatology 2003;38(4):859-68.

Fujiwara D, Hino K, Yamaguchi Y, et al. Type I interferon receptor and response to interferon therapy in chronic hepatitis C patients: a prospective study. J Viral Hepat 2004;11(2):136-40.

Castelruiz Y, Larrea E, Boya P, et al. Interferon alpha subtypes and levels of type I interferon in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology 1999;29(6):1900-4.

Taylor DR, Shi ST & Lai MM. Hepatitis C virus and interferon resistance. Microbes Infect 2000;2(14):1743-56.

Wang Q. Molecular genetics of coronaryartery disease. Curr Opin Cardiol 2005;20(3):182-8.

Topol EJ, Smith J, Plow EF, et al. Genetic susceptibility to myocardial infarction and coronary artery disease. Hum Mol Genet 2006;15(Spec No 2):R117-23.

Suh Y, Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutat Res 2005;573(1-2):41-53.

Barnes E, Webster G, Whalley S, et al. Predictors of a favorable response to alpha interferon therapy for hepatitis C. Clinics Liver Dis 1999;3(4):775-91.

Gallarda JL, Dragon E. Blood screening by nucleic acid amplification technology: current issues, future challenges. Mol Diagn 2000;5(1):11-22.

Gong-Qing Shen, Kalil G. Abdullah, and Qing Kenneth Wang, The TaqMan Method for SNP Genotyping: 2009;293-306.

Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. Nucleic Acids Res 2002;30(6):1292-305.

Tania Mara Welzel, Timothy R. Variants in interferon- Alpha pathway genes and response to pegylated interferonalpha2a plusribavirin for treatment of chronic hepatitis C virus. Hepatology 2009;49(6):1847-58.

Matsuyama N, Mishiro S, Sugimoto M, et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol Res 2003;25(3):221-5.

Cook L, Sullivan K, Krantz EM, et al. Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes. J Clin Microbiol 2006;44(11):4149-56.

How to Cite
Heidari Z, Shahzamani K, Ghanbari R, Tahamsebifar A. Association of SNPs in interferon receptor genes in chronic hepatitis C with response to combined therapy of interferon and ribavirin. Acta Med Iran. 52(10):740-747.